Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
This is a phase II trial of gemcitabine, carboplatin, and bevacizumab in chemotherapy naïve
patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate the time to disease progression; To define the safety of combination therapy with bevacizumab, gemcitabine, and carboplatin in patients with advanced/metastatic TCC.
Dean Bajorin, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|
|Memorial Sloan-Kettering Cancer Center at Mercy Medical Center||Rockville Centre, New York 11570|
|Memorial Sloan-Kettering at Basking Ridge||Basking Ridge, New Jersey 07920|
|Memoral Sloan Kettering Cancer Center||Basking Ridge, New Jersey|
|Memorial Sloan-Kettering Cancer Center @ Suffolk||Commack, New York 11725|
|Memoral Sloan Kettering Cancer Center@Phelps||Sleepy Hollow, New York|